🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

BEst Size for Ovulation Triggering in Poseidon 4 Patients (BEST 4 Study)

Recruitingn/aAges 35 Years - 44 YearsFemaleCentrum Clinic IVF Center
NCT06433518 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This observational clinical study aims to determine the optimal timing of ovulation triggering in women aged 35 and above with poor ovarian reserve. For this purpose, cases undergoing ovarian stimulation for assisted reproductive treatment and planned final oocyte triggering will be evaluated in two separate groups: 1. \*\*Experimental Group\*\*: Final oocyte triggering will be performed when the follicle or follicles measure between 13-16 mm. 2. \*\*Control Group\*\*: Final oocyte triggering will be performed when the follicle or follicles measure greater than 17 mm. All triggers will be administered uniformly with 6500 units of recombinant hCG and 0,2 mg triptorelin injections. The primary outcome of the study will be the number of mature oocytes. Secondary outcomes will include fertilization rates, embryo counts, and implantation rates. Primary and secondary outcomes will be comp

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Women age equal to or greater than 35 years * Women with low serum AMH (\<1,2 ng/ml), * women with low AFC (\<5) * women Undergoing assisted reproduction with Short antagonist protocol or long -agonist protocol * women who used Max daily gonadotropin dose of 300 IU Exclusion Criteria: * Age \<35 years. * Ovarian reserve parameters not meeting the POSEIDON group 4 definition. * Natural or modified natural cycles without controlled ovarian stimulation. * In vitro maturation (IVM) cycles. * Luteal-phase stimulation or DuoStim protocols. * Preimplantation genetic testing (PGT-A, PGT-M, or PGT-SR) cycles, unless prespecified for stratified analyses. * Major untreated uterine cavity pathology (e.g., submucosal fibroids, significant intrauterine adhesions, congenital uterine anomalies) or untreated hydrosalpinx. * Cycles with missing or incomplete follicular measurement data on the trigger day. * Cycles with non-standardized or undocumented trigger-to-oocyte retrieval intervals.
💊

What it tests

  • Ovulation Trigger Timing Based on Leading Follicle Size in POSEIDON Group 4 IVF Patients
📍

Where

1 site
Centrum Clinic IVF Center
Ankara, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy